Insmed (INSM) vs Jazz Pharmaceuticals (JAZZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Jazz Pharmaceuticals (JAZZ) has outperformed Insmed (INSM) over the past year, gaining 68.4% versus a loss of 37.3%. Over five years, INSM leads with a +284.1% price change compared with +64.3% for JAZZ. Insmed is the larger company by market cap ($21.94 billion vs $14.44 billion), about 1.5 times the size.
On valuation, Jazz Pharmaceuticals trades at a lower forward P/E (8.6x vs 127.6x for Insmed). Jazz Pharmaceuticals converts more of its revenue into profit, with a net margin of -8.3% versus -210.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INSM | JAZZ |
|---|---|---|
| Share price | $100.48 | $222.45 |
| Market cap | $21.94B | $14.44B |
| 1-day change | -1.24% | -3.78% |
| YTD return | -41.54% | +35.99% |
| 1-year return | -37.32% | +68.36% |
| 5-year return | +284.07% | +64.31% |
| P/E ratio (TTM) | — | 15.25 |
| Forward P/E | 127.61 | 8.58 |
| EPS (TTM) | $-4.10 | $14.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $606.42M | $4.27B |
| Revenue growth (YoY) | +66.73% | +4.88% |
| Net income (latest FY) | $-1.28B | $-356.15M |
| Gross margin | 79.73% | — |
| Operating margin | -205.59% | -10.08% |
| Net margin | -210.54% | -8.35% |
| 52-week high | $212.75 | $266.38 |
| 52-week low | $90.39 | $128.80 |
| Distance from 52-week high | -52.77% | -16.49% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +96.80% | +32.39% |
| Average volume | 2.57M | 850.55K |
| Shares outstanding | 218.38M | 64.91M |
| Employees | 1,664 | 2,890 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JAZZ has outperformed INSM by 105.7 percentage points over the past year.
- Jazz Pharmaceuticals is more profitable, keeping -8.3 cents of every revenue dollar as net income versus -210.5 cents for Insmed.
- Insmed grew revenue faster in its latest fiscal year (+66.73% vs +4.88%).
About Insmed
INSM stock →Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,664 employees
About Jazz Pharmaceuticals
JAZZ stock →Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,890 employees
INSM vs JAZZ FAQ
Which is bigger, Insmed or Jazz Pharmaceuticals?
Insmed (INSM) is larger, with a market capitalization of $21.94B compared with $14.44B for Jazz Pharmaceuticals (JAZZ).
Which stock has performed better over the past year, INSM or JAZZ?
JAZZ returned +68.36% over the past 12 months, compared with -37.32% for INSM (price return, excluding dividends). Past performance does not predict future results.
Are Insmed and Jazz Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.